Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: TheNewswire.com

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  238.38
+4.73 (2.02%)
AAPL  260.48
-0.01 (-0.00%)
AMD  245.04
+8.40 (3.55%)
BAC  52.54
-0.17 (-0.32%)
GOOG  315.72
-0.65 (-0.21%)
META  629.86
+1.47 (0.23%)
MSFT  370.87
-2.20 (-0.59%)
NVDA  188.63
+4.72 (2.57%)
ORCL  138.09
+0.23 (0.17%)
TSLA  348.95
+3.33 (0.96%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.